Clinical Trials Logo

Mycosis Fungoides clinical trials

View clinical trials related to Mycosis Fungoides.

Filter by:

NCT ID: NCT06285370 Recruiting - Clinical trials for Cutaneous T-Cell Lymphoma

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

Start date: May 29, 2023
Phase: Phase 4
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of mogamulizumab (KW-0761) in chinese subjects with mycosis fungoides or sézary syndrome previously treated with systemic therapy

NCT ID: NCT06235281 Recruiting - Mycosis Fungoides Clinical Trials

Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)

PLIGHT
Start date: February 2024
Phase: Early Phase 1
Study type: Interventional

This is an open label, single arm, single-center, pilot study of concurrent phototherapy and POTELIGEO (mogamulizumab-kpkc) in early-stage mycosis fungoides.

NCT ID: NCT06207812 Recruiting - Mycosis Fungoides Clinical Trials

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis

Start date: January 19, 2024
Phase:
Study type: Observational

To follow up with all our participants with juvenile-onset mycosis fungoides, check on their status, and ask them or their parents about long term outcomes associated with their condition.

NCT ID: NCT06149247 Recruiting - Clinical trials for Cutaneous T-Cell Lymphoma/Mycosis Fungoides

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Start date: December 5, 2023
Phase: Phase 2
Study type: Interventional

The objective of this clinical study is to compare the safety and effectiveness of Valchlor versus HyBryte following 12 weeks of treatment.

NCT ID: NCT06113081 Not yet recruiting - Clinical trials for Cutaneous T Cell Lymphoma

Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

FIL_MOGA
Start date: January 2024
Phase:
Study type: Observational

This study is designed to describe the clinical activity and safety profile of mogamulizumab at standard dose in the treatment of CTCL patients in real world setting

NCT ID: NCT05978141 Recruiting - Clinical trials for Angioimmunoblastic T-cell Lymphoma

A Registry for People With T-cell Lymphoma

Start date: July 27, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

NCT ID: NCT05944562 Recruiting - Mycosis Fungoides Clinical Trials

Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome

Start date: January 9, 2024
Phase: Phase 1
Study type: Interventional

The hypotheses of this study are that single agent CPI-0209 will be safe and well tolerated in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have had at least one prior systemic therapy, and that in these patients, CPI-0209 will demonstrate efficacy and be worth of further study.

NCT ID: NCT05904522 Recruiting - Mycosis Fungoides Clinical Trials

Histopathological Changes in Mycosis Fungoides

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Patients with mycosis fungoides stage 1A disease have patch and plaque lesions less than %10 of body skin area. Aim of the study is to compare lesional and non-lesional skin of mycosis fungoides patients, and to decide if the systemic treatment is better or local treatment is better for them. Two biopsies for each patient were taken from lesional and non-lesional skin area.

NCT ID: NCT05879458 Recruiting - Mycosis Fungoides Clinical Trials

Ritlecitinib in CTCL

Start date: May 17, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to evaluate the effectiveness and safety of Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a rare type of cancer that starts in the white blood cells and eventually can result in rashes or tumors in the skin. This study includes a 24 week Treatment Period and a 24 week Follow-up Period. This study will involve physical examinations, visual assessments, laboratory tests, PET-CT scans, electrocardiograms, photographs of your skin, skin biopsies, and hearing tests.

NCT ID: NCT05872854 Recruiting - Mycosis Fungoides Clinical Trials

Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light

RW-HPN-MF-01
Start date: August 21, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to assess the benefit of continuous treatment with synthetic hypericin ointment (HyBryte) and visible light in patients with mycosis fungoides for up to 12 months (54 weeks). Funding Source: FDA OOPD.